BMCM
NBSE

Bryn Mawr Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Bryn Mawr Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36
Closed -$3K – 92
2018
Q3 		$3K Hold
36
– – ﹤0.01% 88
2018
Q2 		$3K Hold
36
– – ﹤0.01% 93
2018
Q1 		$3K Buy
+36
New +$5.35K ﹤0.01% 85

Other funds holding NBSE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bryn Mawr Capital Management's NBSE Position: Q4 2018 in Review

Bryn Mawr Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2018, closing a stake of 36 shares — an estimated $3K sold.

Bryn Mawr Capital Management first reported a position in NBSE in Q1 2018 and held it in 3 quarters. The position peaked at $3K in Q3 2018. 24 funds tracked by Wall St. Rank hold NBSE as of Q4 2018.

  • Bryn Mawr Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Bryn Mawr Capital Management sold 36 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $3K.
  • Bryn Mawr Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Bryn Mawr Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $3K in Q3 2018.
  • 24 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Bryn Mawr Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.